As well, another report evinced that non-small-cell lung carcinoma (NSCLC) tumor overexpressing both EGFR and HER2 might exhibit higher sensitivity to EGFR tyrosine kinase inhibitor (TKI) compared to EGFR but not HER2 overexpressing tumors [79]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.